Compare GXAI & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GXAI | PPBT |
|---|---|---|
| Founded | 2021 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 2.4M |
| IPO Year | 2022 | 2014 |
| Metric | GXAI | PPBT |
|---|---|---|
| Price | $0.74 | $1.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $30.00 |
| AVG Volume (30 Days) | ★ 2.9M | 2.0M |
| Earning Date | 05-14-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 71.35 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,933,030.00 | N/A |
| Revenue This Year | $271.23 | N/A |
| Revenue Next Year | $36.32 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 47901.74 | N/A |
| 52 Week Low | $0.73 | $0.41 |
| 52 Week High | $2.63 | $5.18 |
| Indicator | GXAI | PPBT |
|---|---|---|
| Relative Strength Index (RSI) | 40.39 | 51.85 |
| Support Level | N/A | $1.35 |
| Resistance Level | $1.29 | $1.85 |
| Average True Range (ATR) | 0.04 | 0.20 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 3.55 | 21.00 |
Gaxos.AI Inc is a technology company focused on reshaping the way people interact with artificial intelligence across everyday life and high-impact industries. It is engaged in building a portfolio of AI-powered solutions designed to make advanced technology more practical, accessible, and transformative. The company's portfolio spans defense, health and wellness, entertainment, and productivity - bringing intelligent tools to markets where innovation can drive meaningful real-world outcomes. It operates as a single operating segment technology-based company that is developing applications aimed at redefining the way it utilizes artificial intelligence (AI) to optimize the user experience.
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.